Carbogen Amcis

Executive Summary

Carbogen Amcis is a Swiss-based Contract Development and Manufacturing Organization (CDMO) with deep expertise in active pharmaceutical ingredients (APIs) and sterile injectable drug products. Founded in 1995 and headquartered in Bubendorf, the company also operates a specialty chemicals division producing cholesterol, vitamin D analogs, and lanolin derivatives. As a private firm, Carbogen Amcis serves the pharmaceutical industry by offering comprehensive services from early development through commercial manufacturing, positioning itself as a reliable partner for both small molecules and complex drug delivery systems. The company's integrated capabilities in drug substance and drug product manufacturing, combined with its specialty chemicals portfolio, provide a diversified revenue stream and competitive advantage in the CDMO market. Looking ahead, Carbogen Amcis is well-positioned to capitalize on the growing demand for outsourced pharmaceutical manufacturing, particularly in sterile injectables and high-potency compounds. The company's strong track record and regulatory expertise make it an attractive partner for innovator companies. While specific financial details are not publicly disclosed due to its private status, the CDMO industry is experiencing steady growth driven by increasing R&D outsourcing and biologics demand. Carbogen Amcis's focus on niche areas like vitamin D analogs and cholesterol derivatives adds a unique dimension to its business model, potentially sheltering it from broader market fluctuations.

Upcoming Catalysts (preview)

• TBDCapacity expansion for sterile injectables70% success
• TBDNew long-term manufacturing contracts with pharma partners60% success
• TBDRegulatory approval for expanded API manufacturing facility75% success